Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J mice

J Neurol Sci. 2015 Sep 15;356(1-2):157-62. doi: 10.1016/j.jns.2015.06.042. Epub 2015 Jun 24.

Abstract

The dysferlin-deficient A/J mouse strain represents a homologous model for limb-girdle muscular dystrophy 2B. We evaluated the disease phenotype in 10 month old A/J mice compared to two dysferlin-sufficient, C57BL/6 and A/JOlaHsd, mouse lines to determine which functional end-points are sufficiently sensitive to define the disease phenotype for use in preclinical studies in the A/J strain. A/J mice had significantly lower open field behavioral activity (horizontal activity, total distance, movement time and vertical activity) when compared to C57BL/6 and A/JoIaHsd mice. Both A/J and A/JOIaHsd mice showed decreases in latency to fall with rotarod compared to C57BL/6. No changes were detected in grip strength, force measurements or motor coordination between these three groups. Furthermore, we have found that A/J muscle shows significantly increased levels of the pro-inflammatory cytokine TNF-α when compared to C57BL/6 mice, indicating an activation of NF-κB signaling as part of the inflammatory response in dysferlin-deficient muscle. Therefore, we assessed the effect of celastrol (a potent NF-κB inhibitor) on the disease phenotype in female A/J mice. Celastrol treatment for four months significantly reduced the inflammation in A/J muscle; however, it had no beneficial effect in improving muscle function, as assessed by grip strength, open field activity, and in vitro force contraction. In fact, celastrol treated mice showed a decrease in body mass, hindlimb grip strength and maximal EDL force. These findings suggest that inhibition of inflammation alone may not be sufficient to improve the muscle disease phenotype in dysferlin-deficient mice and may require combination therapies that target membrane stability to achieve a functional improvement in skeletal muscle.

Keywords: Celastrol; Dysferlin; Inflammation; Muscular dystrophy; NF-κB; Skeletal muscle.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Analysis of Variance
  • Animals
  • Body Weight / drug effects
  • Cytokines / metabolism
  • Disease Models, Animal
  • Dysferlin
  • Echocardiography
  • Female
  • Gene Expression Regulation / drug effects
  • In Vitro Techniques
  • Inflammation / drug therapy*
  • Inflammation / etiology
  • Male
  • Membrane Proteins / deficiency*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Mutant Strains
  • Muscle Strength / drug effects
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / pathology
  • Muscular Dystrophies, Limb-Girdle / complications
  • Muscular Dystrophies, Limb-Girdle / drug therapy*
  • Triterpenes / toxicity*

Substances

  • Cytokines
  • Dysf protein, mouse
  • Dysferlin
  • Membrane Proteins
  • Triterpenes
  • tripterine

Supplementary concepts

  • Limb-girdle muscular dystrophy, type 2B